Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms
2009 (English)In: Expert Review of Hematology, ISSN 1747-4086, Vol. 2, no 1, 81-91 p.Article in journal (Refereed) Published
Patients with chronic myeloid leukemia who fail to achieve timely treatment responses have a worse prognosis. Although many patients respond well to first-line treatment with imatinib, a significant proportion relapse or experience an inadequate response. Since effective alternative Bcr-Abl inhibitors are available (i.e., dasatinib or nilotinib), several regional groups have proposed milestones for imatinib failure or suboptimal response based on the achievement of specified levels of response within a defined treatment duration. A suboptimal response indicates that, although patients may continue to receive a benefit from continuing imatinib treatment at the assigned dose, long-term outcome may be better with an alternative strategy. The underlying mechanisms behind suboptimal responses are multifactorial and may differ from those causing relapse.
Place, publisher, year, edition, pages
2009. Vol. 2, no 1, 81-91 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-170108DOI: 10.1586/17474086.2.1.81PubMedID: 21082997OAI: oai:DiVA.org:uu-170108DiVA: diva2:508306